These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 16775185)
1. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival. Hayes VM; Severi G; Southey MC; Padilla EJ; English DR; Hopper JL; Giles GG; Sutherland RL Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1223-5. PubMed ID: 16775185 [TBL] [Abstract][Full Text] [Related]
2. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. Lindmark F; Zheng SL; Wiklund F; Bensen J; Bälter KA; Chang B; Hedelin M; Clark J; Stattin P; Meyers DA; Adami HO; Isaacs W; Grönberg H; Xu J J Natl Cancer Inst; 2004 Aug; 96(16):1248-54. PubMed ID: 15316060 [TBL] [Abstract][Full Text] [Related]
3. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA. Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173 [TBL] [Abstract][Full Text] [Related]
4. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Ewart-Toland A; Chan JM; Yuan J; Balmain A; Ma J Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):759-64. PubMed ID: 15159307 [TBL] [Abstract][Full Text] [Related]
5. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Severi G; Hayes VM; Padilla EJ; English DR; Southey MC; Sutherland RL; Hopper JL; Giles GG Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):610-2. PubMed ID: 17372260 [TBL] [Abstract][Full Text] [Related]
6. Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population. Paz-y-Miño C; Witte T; Robles P; Llumipanta W; Díaz M; Arévalo M Cancer Genet Cytogenet; 2009 Mar; 189(2):71-6. PubMed ID: 19215786 [TBL] [Abstract][Full Text] [Related]
7. Y chromosome haplotypes and prostate cancer in Sweden. Lindström S; Adami HO; Adolfsson J; Wiklund F Clin Cancer Res; 2008 Oct; 14(20):6712-6. PubMed ID: 18927315 [TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer. Elkins DA; Yokomizo A; Thibodeau SN; J Schaid D; Cunningham JM; Marks A; Christensen E; McDonnell SK; Slager S; J Peterson B; J Jacobsen S; R Cerhan J; L Blute M; J Tindall D; Liu W Prostate; 2003 Jun; 56(1):30-6. PubMed ID: 12746844 [TBL] [Abstract][Full Text] [Related]
10. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Johansson M; McKay JD; Rinaldi S; Wiklund F; Adami HO; Grönberg H; Kaaks R; Stattin P Prostate; 2009 Sep; 69(12):1281-91. PubMed ID: 19455605 [TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cicek MS; Liu X; Schumacher FR; Casey G; Witte JS Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2549-52. PubMed ID: 17164384 [TBL] [Abstract][Full Text] [Related]
12. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women. Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674 [TBL] [Abstract][Full Text] [Related]
13. Variants in circadian genes and prostate cancer risk: a population-based study in China. Chu LW; Zhu Y; Yu K; Zheng T; Yu H; Zhang Y; Sesterhenn I; Chokkalingam AP; Danforth KN; Shen MC; Stanczyk FZ; Gao YT; Hsing AW Prostate Cancer Prostatic Dis; 2008; 11(4):342-8. PubMed ID: 17984998 [TBL] [Abstract][Full Text] [Related]
14. Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Nam RK; Zhang WW; Klotz LH; Trachtenberg J; Jewett MA; Sweet J; Toi A; Teahan S; Venkateswaran V; Sugar L; Loblaw A; Siminovitch K; Narod SA Clin Cancer Res; 2006 Nov; 12(21):6452-8. PubMed ID: 17085659 [TBL] [Abstract][Full Text] [Related]
15. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Hayes VM; Severi G; Eggleton SA; Padilla EJ; Southey MC; Sutherland RL; Hopper JL; Giles GG Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):993-6. PubMed ID: 15824176 [TBL] [Abstract][Full Text] [Related]
16. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Wang L; McDonnell SK; Slusser JP; Hebbring SJ; Cunningham JM; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN Cancer Res; 2007 Apr; 67(7):2944-50. PubMed ID: 17409399 [TBL] [Abstract][Full Text] [Related]
17. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093 [TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765 [TBL] [Abstract][Full Text] [Related]
19. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Stevens VL; Rodriguez C; Talbot JT; Pavluck AL; Thun MJ; Calle EE Prostate; 2008 Sep; 68(12):1336-40. PubMed ID: 18500687 [TBL] [Abstract][Full Text] [Related]
20. Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy. Meyer A; Schürmann P; Ghahremani M; Kocak E; Brinkhaus MJ; Bremer M; Karstens JH; Hagemann J; Machtens S; Dörk T Urol Oncol; 2009; 27(4):373-6. PubMed ID: 18625567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]